Breaking News

Product Candidate Applying GlymaxX Makes It into Clinical Phase I

Abcuro announces initial data on ABC008.

ProBioGen, a premier CDMO, has announced that another product candidate applying its antibody-dependent cellular cytotoxicity (ADCC) enhancement technology GlymaxX has entered clinical development.   Abcuro, a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise targeting of cytotoxic T cells, recently announced initial  data on ABC008, for which ProBioGen generated the production clone applying its proprietary GlymaxX technology and produc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters